<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7395">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03010657</url>
  </required_header>
  <id_info>
    <org_study_id>HREBA-CC-16-0851</org_study_id>
    <nct_id>NCT03010657</nct_id>
  </id_info>
  <brief_title>Evaluation of a Food Intake Modification for Lung Cancer Patients</brief_title>
  <official_title>Evaluation of a Food Intake Modification for Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates a diet modification in adults undergoing chemotherapy for non-small
      cell lung cancer. Half of participants will modify their diet, while the other half will
      continue to eat their habitual diet.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in computed tomography-derived muscle mass</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in strength</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>hand grip</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in physical performance</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>short physical performance battery protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response to therapy</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>change in computed tomography-derived tumor size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-induced toxicity</measure>
    <time_frame>6 weeks</time_frame>
    <description>National Cancer Institute Common Toxicity Criteria for toxicity grading</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in quality of life</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (30 and LC13)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in inflammatory status</measure>
    <time_frame>Baseline and 10 weeks</time_frame>
    <description>C-reactive protein/albumin ratio</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>Antineoplastic Agents</condition>
  <arm_group>
    <arm_group_label>Food Intake Modification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Habitual Food Intake</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Food Intake Modification</intervention_name>
    <arm_group_label>Food Intake Modification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Habitual Food Intake</intervention_name>
    <arm_group_label>Habitual Food Intake</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a newly confirmed diagnosis of non-small cell lung cancer scheduled for
             first line chemotherapy

          -  Patients with a computed tomography (CT) image, which includes scans of the 3rd
             lumbar region, taken within 45 days before initiation of chemotherapy

          -  Confirmed dietary intake of a specific food group at or below Canada's Food Guide
             age-specific recommended number of servings per day

          -  Ability to maintain oral intake

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 / Karnofsky
             Performance Status between 60-100

          -  Ability to give written, informed consent

        Exclusion Criteria:

          -  Co-morbidities that would be expected to interfere with the primary outcome measure

          -  Patients on long term drugs or supplements that modify muscle metabolism

          -  Life expectancy &lt;3 months

          -  Individuals with specific food intolerances or allergies

          -  An inability to comply with study instructions

          -  Patients without a computed tomography (CT) image, which includes scans of the 3rd
             lumbar region, taken after 2 cycles of chemotherapy

          -  Patients engaged in a total of ≥50 minutes of moderate-to-vigorous cardiovascular
             exercise per week and/or structured resistance exercise occurring ≥2 times per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vera Mazurak, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Martins, Ph.D.</last_name>
    <email>karen.martins@ualberta.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 4, 2017</lastchanged_date>
  <firstreceived_date>December 20, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
